NCT01730222View on ClinicalTrials.gov

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

August 31, 2017

Conditions
Pancreatic Cancer
Interventions
DRUG

cisplatin

cisplatin at 30 mg/m2 on days 1 and 15

DRUG

capecitabine

capecitabine at 1250 mg/ m2 days 1-28

DRUG

gemcitabine

gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B

DRUG

nab-paclitaxel

nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B

Trial Locations (1)

20132

IRCCS S Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT01730222 - A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter